combining glp-1 receptor agonist with dpp-4 inhibitor not recommended guideline Clinical Use of Inhibitors do not combine dpp-4 inhibitors
Description
2025;48(Supplement1):S181206

It is unclear whether individuals taking GLP-1RA have inadequate nutritional status or if their nutrient needs exceed the DRI standards
Researchers now understand that GLP-1 operates as a metabolic hormone while also serving as an anti-inflammatory agent that functions within synovial spaces

Wegovy is licensed in the UK in doses up to 2.4mg for weight loss and, on 14 September 2025, Novo Nordisk published results of a phase IIIb clinical trial (STEP UP, NCT05646706) of a 7.2mg dose of semaglutide for subcutaneous injection 1

Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic poly-peptide (GIP, previously known as gastric inhibitory polypeptide) are key incretin hormones secreted from the small intestine after oral intake of food

Impact of obesity in asthma: Possible future therapies
